ZENZ, T., D. VOLLMER, Martin TRBUŠEK, Jana ŠMARDOVÁ, A. BENNER, T. SOUSSI, H. HELFRICH, M. HEUBERGER, P. HOTH, M. FUGE, T. DENZEL, S. HÄBE, Jitka MALČÍKOVÁ, Petr KUGLÍK, S. TRUONG, N. PATTEN, L. WU, D. OSCIER, R. IBBOTSON, A. GARDINER, I. TRACY, K. LIN, A. PETTITT, Šárka POSPÍŠILOVÁ, Jiří MAYER, M. HALLEK, H. DÖHNER and S. STILGENBAUER. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia. England: Nature Publishing Group, 2010, vol. 24, No 12, p. 2072-2079. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/leu.2010.208.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
Name in Czech Profil TP53 mutací u chronické lymfocytární leukémie: průkaz CLL specifického profilu komplexní analýzou 268 mutací.
Authors ZENZ, T. (276 Germany, guarantor), D. VOLLMER (276 Germany), Martin TRBUŠEK (203 Czech Republic, belonging to the institution), Jana ŠMARDOVÁ (203 Czech Republic, belonging to the institution), A. BENNER (276 Germany), T. SOUSSI (752 Sweden), H. HELFRICH (276 Germany), M. HEUBERGER (276 Germany), P. HOTH (276 Germany), M. FUGE (276 Germany), T. DENZEL (276 Germany), S. HÄBE (276 Germany), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Petr KUGLÍK (203 Czech Republic, belonging to the institution), S. TRUONG (250 France), N. PATTEN (250 France), L. WU (250 France), D. OSCIER (840 United States of America), R. IBBOTSON (840 United States of America), A. GARDINER (840 United States of America), I. TRACY (840 United States of America), K. LIN (826 United Kingdom of Great Britain and Northern Ireland), A. PETTITT (826 United Kingdom of Great Britain and Northern Ireland), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), M. HALLEK (826 United Kingdom of Great Britain and Northern Ireland), H. DÖHNER (276 Germany) and S. STILGENBAUER (276 Germany).
Edition Leukemia, England, Nature Publishing Group, 2010, 0887-6924.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 8.966
RIV identification code RIV/00216224:14110/10:00051668
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/leu.2010.208
UT WoS 000285380900012
Keywords in English CLL; genetics; 17p deletion; p53; TP53 mutation
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 10/4/2012 08:44.
Abstract
The TP53 mutation profile in chronic lymphocytic leukemia (CLL) and the correlation of TP53 mutations with allele status or associated molecular genetics are currently unknown. We performed a large mutation analysis of TP53 at four centers and characterized the pattern of TP53 mutations in CLL. We report on 268 mutations in 254 patients with CLL. Missense mutations appeared in 74% of cases compared with deletions and insertions (20%), nonsense (4%) and splice site (2%) mutations. The majority (243 of 268) of mutations were located in the DNA-binding domain. Transitions were found in 131 of 268 mutations, with only 41 occurring at methylated CpG sites (15%), suggesting that transitions at CpGs are uncommon. The codons most frequently mutated were at positions 175, 179, 248 and 273; in addition, we detected a common 2-nt deletion in the codon 209. Most mutations (199 of 259) were accompanied by deletion of the other allele (17p-). Interestingly, trisomy 12 (without 17p-) was only found in one of 60 cases with TP53 mutation (without 17p-) compared with 60 of 16 in the cohort without mutation (P=0.006). The mutational profile was not different in the cohorts with and without previous therapy, suggesting that the mechanism underlying the development of mutations may be similar, independent of treatment.
Abstract (in Czech)
U chronické lymfocytární leukémie (CLL) dosud nebyl popsán mutační profil TP53 mutací ani korelace TP53 mutací s alelovým statusem a molekulární genetikou. Provedli jsme mutační analýzu genu TP53 u pacientů ze čtyř center a charakterizovali jsme profil mutací u CLL. Celkem jsme popsali 268 mutací u 254 pacientů.
PrintDisplayed: 25/4/2024 17:52